Bad news continues for CryoLife as tissue company forced to revise 2002 guidance
This article was originally published in Clinica
CryoLife this week revised its guidance downwards for full year 2002, following adverse publicity surrounding its FDA warning letter and investigation (see Clinica No 1016, p 13). Vascular revenues for 2002 will be up 6-8% (compared with earlier predictions of low double-digit growth), and orthopaedics will show similar growth (down from 20%+), said CFO and vice-president Ashley Lee at the company's half-year results announcement. Cardiac revenues will be 4% up.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.